Official Title: “An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia.”

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: Amlodipine/Atorvastatin

Primary Measures

• To evaluate the number of patients who reach target blood pressure (BP) and
• LDL-C targets as defined by their governing guidelines.

Secondary Measures

• To assess changes from baseline to end of treatment for the following efficacy
• parameters: LDL-C, total cholesterol (TC), triglycerides, high-density lipoprotein
• cholesterol (HDL-C), HDL-C/LDL-C ratio, TC/HDL-C ratio. Systolic Blood Pressure
• (SBP) and Diastolic Blood Pressue (DBP).

Inclusion Criteria:

• Patients who are above target LDL-C and BP who are eligible for treatment

Exclusion Criteria:

• High liver enzymes

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 80 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Pfizer

Overall Clinical Trial Officials and Contacts

Pfizer CT.gov Call Center Study Director Pfizer  

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00330785

Study ID Number: A3841018

ClinicalTrials.gov Identifier: NCT00330785

Health Authority: United Kingdom: Department of Health

To obtain contact information for a study center near you, click here.

Link to ClinicalStudyResults.org posting